#Roche’s BTK inhibitor #fenebrutinib just delivered #news at #ACTRIMS2026, with PhIII FENtrepid data in #PPMS showing a 12% reduction in disability progression vs #Ocrevus ipharmacenter.com/post/actrims-2… #pharma #ACTRIMS26 #neurology #multiplesclerosis #ACTRIMS2026 #ACTRIMSForum #media

#EHSF2026 spotlight on #hidradenitisSuppurativa 🔍New 3-year BE HEARD data show UCB’s #bimekizumab (#BIMZELX) delivering: 40.1% IHS4-100 (complete inflammatory lesion resolution) ipharmacenter.com/post/ehsf-2026… #pharma #pharmaceutical #breaking #media #EHSF26 #RheumTwitter #innovation

#EHSF2026 spotlight on #hidradenitisSuppurativa New 3-year BE HEARD data show UCB’s #bimekizumab (#BIMZELX) delivering:40.1% IHS4-100 (complete inflammatory lesion resolution) ipharmacenter.com/post/ehsf-2026… #pharma #pharmaceutical #breaking #media #EHSF26 #RheumTwitter #innovation #news

#Roche’s BTK inhibitor #fenebrutinib just delivered #news at #ACTRIMS2026, with Phase III FENtrepid data in #PPMS ipharmacenter.com/post/actrims-2… #pharma #ACTRIMS26 #breaking #multiplesclerosis #ACTRIMSForum #ACTRIMS2026 #neurology #Neuroscience #innovation #media #pharmaceutical

#Roche’s BTK inhibitor #fenebrutinib just delivered #news at #ACTRIMS2026, with Phase III FENtrepid data in #PPMS showing a 12% reduction in disability progression vs #Ocrevus ipharmacenter.com/post/actrims-2… #pharma #ACTRIMS26 #neurology #multiplesclerosis #ACTRIMSForum #ACTRIMS2026

#EliLilly bets $2.4B on Orna's in vivo CAR-T revolution! Circular RNA reprograms immune cells inside body for autoimmune wins. ipharmacenter.com/post/lilly-to-… #PharmaDeals #CART #Autoimmune #RheumTwitter #pharma #pharmaceutical #breaking #news #media #innovation #immunology #revenues

#EHSF2026: Long‑term BE HEARD data with #bimekizumab in #hidradenitissuppurativa show sustained skin responses and durable control of flares.​ipharmacenter.com/post/ehsf-2026…​ #pharma #pharmaceutical #innovation #RheumTwitter #Dermatology #Immunology #MedTwitter #healthcare #ACR26

#ACTRIMS2026: #Fenebrutinib demonstrates breakthrough results in primary progressive MS, with meaningful reductions in disability progression versus control.​ ipharmacenter.com/post/actrims-2…​ #Neurology #MS #MedTwitter #NeuroTwitter #pharma #Pharmaceutical #Healthcare #ACTRIMS26 #media

#USA #FDA approvals hub: track the latest #oncology, #immunology, #neurology, and rare‑disease decisions with concise clinical and access context. ipharmacenter.com/fda-approvals​ #USFDA #DrugApprovals #MedTwitter #pharma #pharmaceutical #innovation #RheumTwitter #Dermatology #Immunology

Top‑selling #drugs 2026: #Keytruda, GLP‑1s and other #blockbusters are set to dominate global pharma #revenues this year.​ ipharmacenter.com/post/top-selli…​ #Pharma #DrugRevenues #MedTwitter #pharmaceutical #healthcare #drugpricing

#JPM2026: #Lilly, #Novartis, #Merck and #BMS outline next‑wave growth from ADCs, KRAS, radioligands and cell/gene therapies Find our analysis on where top pharma is currently working ipharmacenter.com/post/j-p-morga… #pharma #pharmaceutical #healthcare #globalhealth #innovation

Top 10 #Pharmaceutical Companies by #Revenues 2025 J&J leads the global #pharma league table in 2025, powered by #blockbuster drugs in #oncology and #immunology.ipharmacenter.com/post/top-10-ph… #Pharma #Biopharma #DrugRevenue #Healthcare #Oncology #Immunology #MarketAccess #media #News

Top 10 highest #revenue #drugs of 2025 are out #Keytruda still leads, but GLP‑1/GIP incretins like #Mounjaro, #Ozempic, #Wegovy & #Zepbound are rapidly reshaping the market. ipharmacenter.com/post/the-pharm… #Pharma #Biopharma #TopDrugs #DrugSales #DrugRevenues #innovation #RheumTwitter

#Brazil has updated its #pharmaceutical pricing rules via CMED Resolution No. 3/2025, introducing new categories and stricter reference pricing for better market regulation ipharmacenter.com/post/brazil-he… #DrugPricing #pharma #healthcare #Farmacia #Saúde #SUS #Medicamentos #Farmaceutica

#GSK’s ultra-long-acting IL-5 biologic #Exdensur secured #EU approval for severe #asthma with type 2 inflammation and severe #CRSwNP ipharmacenter.com/post/gsk-s-ult… #RheumTwitter #news #media #breaking #Type2Inflammation #Biologics #Respiratory #Pharma #healthcare #Europe #drugpricing

Top 10 #Pharmaceutical Companies by #Revenues 2025 J&J leads the global #pharma league table in 2025, powered by #blockbuster drugs in #oncology and #immunology.ipharmacenter.com/post/top-10-ph… #Pharma #Biopharma #DrugRevenue #Healthcare #Oncology #Immunology #MarketAccess #media #News

#Amgen’s CD19‑targeted biologic #Uplizna just secured #EuropeanCommission approval as an add‑on therapy for antibody‑positive generalized #myastheniagravis ipharmacenter.com/post/amgen-s-u… #Healthcare #HealthNews #Gesundheit #Gesundheitsnews #Santé #ActualitésSanté #Sanità

#Amgen’s CD19‑targeted biologic #Uplizna just secured #EuropeanCommission approval as an add‑on therapy for antibody‑positive generalized #myastheniagravis ipharmacenter.com/post/amgen-s-u… #NotizieSanitarie #NoticiasDeSalud #EuropeanCommission #EuropäischeKommission #CommissionEuropéenne

#GSK’s ultra-long-acting IL-5 biologic #Exdensur secured #EU approval for severe #asthma with type 2 inflammation and severe #CRSwNP ipharmacenter.com/post/gsk-s-ult… #investors #news #media #breaking #Type2Inflammation #Biologics #Respiratory #Pharma #healthcare #Europe #drugpricing

#Brazil just overhauled its drug pricing rules. CMED Resolution 3/2025 brings new categories, tougher international reference pricing and clearer timelines for PF decisions. We break down what this means for launches and #SUS access ipharmacenter.com/post/brazil-he… #DrugPricing #Saúde